China Injectable Muscle Building Steroid Ethyl Oleate, Find details about China Ethyl Oleate, Drug from Injectable Muscle Building Steroid Ethyl Oleate
Injectable Muscle Building Steroid Ethyl Oleate
Product detail:
Product Name | Ethyl oleate |
CAS | 111-62-6 |
MF | C20H38O2 |
MW | 310.51 |
EINECS | 203-889-5 |
Melting point | −32 °C(lit.) |
Boiling point | 216-218 °C15 mm Hg |
Density | 0.87 g/mL at 25 °C(lit.) |
FEMA | 2450 | ETHYL OLEATE |
refractive index | n20/D 1.451(lit.) |
Flash point | >230 °F |
storage temp | −20°C |
solubility | chloroform: soluble10% |
form | Oily Liquid |
color | Clear |
Sensitive | Light Sensitive |
Merck | 14,6828 |
JECFA Number | 345 |
BRN | 1727318 |
InChIKey | LVGKNOAMLMIIKO-VAWYXSNFSA-N |
Description
Ethyl oleate is a fatty acid ester formed by the condensation of oleic acid and ethanol. It is a colorless to light yellow liquid. Ethyl oleate is produced by the body during ethanol intoxication.Ethyl oleate is used as a solvent for pharmaceutical drug preparations involving lipophilic substances such as steroids. It also finds use as a lubricant and a plasticizer. Louis Bouveault used ethyl oleate to demonstrate Bouveault-Blanc reduction, producing oleyl alcohol and ethanol, a method which was subsequently refined and published in Organic Syntheses.Ethyl oleate is regulated as a food additive by the Food and Drug Administration under "Food Additives Permitted for Direct Addition to Food for Human Consumption", 21CFR172.515. Ethyl oleate has been identified as a primer pheromone in honeybees.Ethyl oleate is one of the fatty acid ethyl esters (FAEE) that is formed in the body after ingestion of ethanol. There is a growing body of research literature that implicates FAEEs such as ethyl oleate as the toxic mediators of ethanol in the body (pancreas, liver, heart, and brain). Among the speculations is that ethyl oleate may be the toxic mediator of alcohol in fetal alcohol syndrome. The oral ingestion of ethyl oleate has been carefully studied and due to rapid degradation in the digestive tract it appears safe for oral ingestion. Ethyl oleate is not currently approved by the U.S. Food and Drug Administration for any injectable use. However, it is used by compounding pharmacies as a vehicle for intramuscular drug delivery, in some cases to prepare the daily doses of progesterone in support of pregnancy. Studies which document the safe use of ethyl oleate in pregnancy for both the mother and the fetus have never been performed.
Ethyl oleate is a long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of oleic acidwith the hydroxy group of ethanol. It has a role as a plant metabolite and an acaricide. It derives from an oleic acid.
Ethyl Oleate is the ester formed by the condensation of the fatty acid, oleic acid and ethanol. It is a clear colourless to pale straw liquid. It is also produced naturally by our body. Ethyl Oleate BP/EP, conforms to the British (BP) and European Pharmacopoeia (Ph.Eur). Ethyl Oleate is a clear and colourless mobile liquid. The BP / Ph.Eur grade has ester value of 94 - 105%. Ethyl Oleate is widely used in pharmaceutical drugs and steroids preparation. It is classified as food and pharma grade.
Abstract
The absorption, distribution, and excretion of radiolabeled ethyl oleate (EO) was studied in Sprague-Dawley rats after a single, peroral dose of 1.7 or 3.4 g/kg body weight and was compared with a radiolabeled triacylglycerol (TG) containing only oleic acid as the fatty acid (triolein). Both test materials were well absorbed with approximately 70-90% of the EO dose absorbed and approximately 90-100% of the TG dose absorbed. At sacrifice (72 h post-dose), tissue distribution of EO-derived radioactivity and TG-derived radioactivity was similar. The tissue with the highest concentration of radioactivity in both groups was mesenteric fat. The other organs and tissues had very low concentrations of test material-derived radioactivity. Both test materials were rapidly and extensively excreted as CO with no remarkable differences between their excretion profiles. Approximately 40-70% of the administered dose for both groups was excreted as CO2 within the first 12 h (consistent with β-oxidation of fatty acids). Fecal elimination of EO appeared to be dose-dependent. At the dose of 1.7 g/kg, 7-8% of the administered dose was eliminated in the feces. At the dose of 3.4 g/kg, approximately 20% of the administered dose was excreted in the feces. Excretion of TG-derived radiolabel in the feces was approximately 2-4% for both doses. Overall, the results demonstrate that the absorption, distribution, and excretion of radiolabeled EO is similar to that of TG providing evidence that the oleic acid moiety of EO is utilized in the body as a normal dietary TG-derived fatty acid. To confirm the expected safety of EO in humans, a total of 235 subjects participated in a 12-week trial where two levels of ethyl oleate in a milk-based beverage were investigated: 8 g/kg). Adverse events(AEs) were recorded throughout the 12-week trial. In addition, a brief physical exam (including vital signs and body weight), ECGs, fasting serum chemistry profile, serum lipid profile, and urinalysis were performed at baseline and after study completion. Results showed the incidence of reported AEs was similar between the EO groups and the control groups. Analysis of comprehensive laboratory data revealed no EO exposure-related, clinically significant adverse changes in laboratory parameters. These studies demonstrated that EO has a highly favorable safety profile and is well tolerated in the diet.